Article
Selective RET kinase inhibition for patients with RET-altered cancers.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2018
Subbiah V, Velcheti V, Tuch B B, Ebata K, Busaidy N L, Cabanillas M E, Wirth L J, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace R D, Hartley D, Rhodes S, Reddy M, Brandhuber B J, Andrews S, Rothenberg S M, Drilon A
Abstract excerpt
Background: Alterations involving the RET kinase are implicated in the pathogenesis of lung, thyroid and other cancers. However, the clinical activity of multikinase inhibitors (MKIs) with anti-RET activity in RET-altered patients appears limited, calling into question the therapeutic potential of targeting RET. LOXO-292 is a selective RET inhibitor designed to inhibit diverse RET fusions, activating mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.